Central Nervous System Lymphoma — Trials

Central Nervous System Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

214 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 81
Recruiting: 54
Ph III recruiting: 5
Growth YoY: —
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 26.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 51–90 of 90 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07416890	Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma	recruiting	Phase 2	24	Zhejiang Cancer HospitalOTHER	1	Feb 18, 2026	clinicaltrials
NCT07410520	PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.	recruiting	Phase 2	50	The First Affiliated Hospital with Nanjing Medical UniversityOTHER	1